ReviewJournal of tropical medicine2022
Natural Products for Cancer Therapy: A Review of Their Mechanism of Actions and Toxicity in the Past Decade.
Review in Journal of tropical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed.
- Identification and validation of a chronic kidney disease prediction model after radical nephrectomy: a multicenter cohort retrospective study.Annals of medicine · 2026Article
- Allosteric Interactions of Flavonoids with ACE2 and Potential Implications for COVID-19: Computational Insights, Metabolic and Mitochondrial Effects of Rutin in A549 Cells.Cell biochemistry and biophysics · 2026Article
- Article
- Narciclasine Exerts Anticancer Activity in Colorectal Cancer Cells in Association with HELLS Downregulation and DNA Damage-Associated Responses.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Luteolin as a Cancer Therapeutic: From Preclinical Evidence to Translational Potential.Chemistry & biodiversity · 2026Review
- Natural Products as Promising Pharmacological Agents Against Cancer: A Holistic Overview of Their Anti-Cancer Mechanisms of Action of the Last Five Years.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Phytochemical Profile and In Vivo Assessment of Toxicity and Anti-Inflammatory Activity ofPlants (Basel, Switzerland) · 2026Article
- Timosaponin AIII enhances CAR-T cell potency and prevents relapse through impairing CAR-Tregs.Nature communications · 2026Article
- Article
- Article
- Network pharmacology-guided identification of Rabdosia rubescent as a suppressor of laryngeal cancer via MMP9-mediated extracellular matrix remodeling: integratedFrontiers in pharmacology · 2026Article
- Screening the Active Phytochemicals FromCancer innovation · 2025Review
- Design, Synthesis, and Selective Antiproliferative Activity of Indolizine Derivatives as Microtubule Destabilizers.Archiv der Pharmazie · 2025Article
- A Bibenzyl fromAntioxidants (Basel, Switzerland) · 2025Article
- Regulation of Cell Cycle-Related Damage/Repair Mechanism and Oxidative Stress Status by Oroxylin A in Hepatocellular Carcinoma Cells.International journal of molecular sciences · 2025Article
- Article
- Isorhamnetin: Reviewing Recent Developments in Anticancer Mechanisms and Nanoformulation-Driven Delivery.International journal of molecular sciences · 2025Review
- Bioactive Plant-Derived Compounds as Novel Perspectives in Oral Cancer Alternative Therapy.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Nature-Inspired Strategies in Cancer Management: The Potential of Plant Extracts in Modulating Tumour Biology.International journal of molecular sciences · 2025Review
- Novel 3,19-(N-Phenyl-3-(4-fluorophenyl)-pyrazole) Acetal of Andrographolide Promotes Cell Cycle Arrest and Apoptosis in MDA-MB-231 Breast Cancer Cells.Pharmaceuticals (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The ethnopharmacological information gathered over many centuries and the presence of diverse metabolites have made the medicinal plants as the prime source of drugs. Despite the positive attributes of natural products, there are many questions pertaining to their mechanism of actions and molecular targets that impede their development as therapeutic agents. One of the major challenges in cancer research is the toxicity exerted by investigational agents towards the host. An understanding of their molecular targets, underlying mechanisms can reveal their anticancer efficacy, help in optimal therapeutic dose selection, to mitigate their side effects and toxicity towards the host. The purpose of this review is to collate details on natural products that are recently been investigated extensively in the past decade for their anticancer potential. Besides, critical analysis of their molecular targets and underlying mechanisms on multiple cancer cell lines, an in-depth probe of their toxicological screening on rodent models is outlined as well to observe the prevalence of their toxicity towards host. This review can provide valuable insights for researchers in developing methods, strategies during preclinical and clinical evaluation of anticancer candidates.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.